Please login to the form below

Not currently logged in
Email:
Password:

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

Herceptin

A US FDA advisory committee gave its blessing to two biosimilar versions of Roche's cancer antibodies Avastin and Herceptin yesterday, raising the prospect of cut-price competition to two of the company's biggest selling products.

Amgen and Allergan got a unanimous vote in favour of approving their biosimilar of Avastin (bevacizumab) in the morning yesterday, while Mylan and Biocon got the go-ahead in the afternoon for their Herceptin (trastuzumab) rival. In both cases, panellists concluded there were no clinically meaningful differences between the reference products and the biosimilars.

Amgen and Allergan's candidate is the first biosimilar of Avastin to reach this stage and the FDA is now scheduled to make a decision on the marketing application in September, although a launch will depend on the outcome of ongoing patent litigation with Roche.

Mylan meanwhile is also pitching at a September verdict for its drug, and recently agreed a settlement deal with Roche to clear the way for a US launch if approved by the FDA.

Avastin is indicated for a range of solid tumours and brought in $7bn in sales last year - almost $3bn from the US market. Meanwhile, sales of HER2-positive breast cancer therapy Herceptin also approached $7bn in 2016 with around $2.5bn from the US.

Roche may not have to worry too much however, at least in the short-term. Biosimilars do not tend to prompt the massive reduction in sales seen when generics are launched for traditional pharmaceuticals, as they are still costly to produce and so are generally priced at less of a discount.

Meanwhile, the Swiss group is in the midst of a fertile launch period for new medicines, with four new drugs - Cotellic (cobimetinib) for melanoma, Alecensa (alectinib) for lung cancer, leukaemia therapy Venclexta (venetoclax) and PD-L1 inhibitor Tecentriq (atezolizumab) for bladder and lung cancer - rolling out onto the market.

Of these, Tecentriq and Venclexta alone have been predicted to add nearly $4bn to Roche sales in 2021, according to a recent EvaluatePharma report, which should help offset a predicted $5.5bn reduction in global Herceptin and Avastin sales in 2022.

Article by
Phil Taylor

14th July 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics